Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens

Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025

Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents.

Pegg, A. E. (1990) · PubMed · Cited by 730

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 661

PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme

Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N. L., O'Fallon, J. R., Schaefer, P., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 387

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme

Giannini, C., Sarkaria, J. N., Saito, A., Uhm, J. H., Galanis, E., Carlson, B. L., Schroeder, M. A., & James, C. D. (2005) · Neuro-Oncology · doi:10.1215/s1152851704000821 · Cited by 326

Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response

Sarkaria, J. N., Carlson, B. L., Schroeder, M. A., Grogan, P., Brown, P. D., Giannini, C., Ballman, K. V., Kitange, G. J., Guha, A., Pandita, A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2510 · Cited by 270

Genomic Changes and Gene Expression Profiles Reveal That Established Glioma Cell Lines Are Poorly Representative of Primary Human Gliomas

Li, A., Walling, J., Kotliarov, Y., Steed, M. E., Ahn, S. J., Rosenblum, M., Mikkelsen, T., Zenklusen, J. C., & Fine, H. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0280 · Cited by 264

Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR

Pandita, A., Aldape, K., Zadeh, G. M., Guha, A., & James, C. D. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10300 · Cited by 212

Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas

Higgins, D. M. O., Caliva, M. J., Schroeder, M. A., Carlson, B. L., Upadhyayula, P. S., Milligan, B. D., Cheshier, S. H., Weissman, I. L., Sarkaria, J. N., Meyer, F. B., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07694-4 · Cited by 29

A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

Yu, S., Wei, S., Savani, M. R., Lin, X., Du, K., Mender, I., Siteni, S., Vasilopoulos, T., Reitman, Z. J., Ku, Y., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0374 · Cited by 31

RBBP4-p300 axis modulates expression of genes essential for cell survival and is a potential target for therapy in glioblastoma

Mladek, A. C., Yan, H., Tian, S., Decker, P. A., Burgenske, D. M., Bakken, K. K., Hu, Z., He, L., Connors, M. A., Carlson, B. L., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac051 · Cited by 29

P21 Overexpression Promotes Cell Death and Induces Senescence in Human Glioblastoma

Mansour, M. A., Rahman, M., Ayad, A. A., Warrington, A. E., & Burns, T. C. (2023) · Cancers · doi:10.3390/cancers15041279 · Cited by 29

Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma

Laramy, J. K., Kim, M., Gupta, S. K., Parrish, K. E., Zhang, S., Bakken, K. K., Carlson, B. L., Mladek, A. C., Ma, D. J., Sarkaria, J. N., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.243477 · Cited by 29

Perfused Three-dimensional Organotypic Culture of Human Cancer Cells for Therapeutic Evaluation

Wan, X., Ball, S., Willenbrock, F. W., Yeh, S. A., Vlahov, N., Koennig, D., Green, M., Brown, G., Jeyaretna, D. S., Li, Z., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09686-0 · Cited by 28

Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival

Muller-Greven, G. M., Carlin, C. R., Burgett, M. E., Ahluwalia, M. S., Lauko, A. J., Nowacki, A. S., Herting, C. J., Qadan, M. A., Bredel, M., Toms, S. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0249 · Cited by 28

Differential expression of an endogenous retroviral element [HERV-K(HML-6)] is associated with reduced survival in glioblastoma patients

Shah, A. H., Govindarajan, V., Doucet-O’Hare, T. T., Rivas, S. R., Ampie, L., DeMarino, C., Banasavadi‐Siddegowda, Y., Zhang, Y., Johnson, K. R., Almsned, F. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-10914-5 · Cited by 28

Pre-clinical models for evaluating glioma targeted immunotherapies

Frederico, S. C., Zhang, X., Hu, B., & Kohanbash, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1092399 · Cited by 27

The novel BET inhibitor UM-002 reduces glioblastoma cell proliferation and invasion

Jermakowicz, A. M., Rybin, M. J., Suter, R. K., Sarkaria, J. N., Zeier, Z. R., Feng, Y., & Ayad, N. G. (2021) · Scientific Reports · doi:10.1038/s41598-021-02584-6 · Cited by 29

Iron oxide nanoparticle-mediated radiation delivery for glioblastoma treatment

Chiarelli, P. A., Revia, R. A., Stephen, Z. R., Wang, K., Kievit, F. M., Sandhu, J., Upreti, M., Chung, S., Ellenbogen, R. G., & Zhang, M. (2022) · Materials Today · doi:10.1016/j.mattod.2022.04.001 · Cited by 27

Financial impact of oral chemotherapy wastage on society and the patient

Monga, V., Meyer, C., Vakiner, B., & Clamon, G. H. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218762596 · Cited by 26

Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma

Narayan, R. S., Gasol, A., Slangen, P. L. G., Cornelissen, F. M. G., Lagerweij, T., Veldman, H. Y. Y. E., Dik, R., van den Berg, J., Slotman, B. J., Würdinger, T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0480 · Cited by 25

Targeted suppression of glioma by ultralow-dose x-ray–induced photodynamic therapy and gold-based nanoclusters in preclinical models

Li, S., Chen, S., Li, Y., Sun, W., Li, J., Deng, H., Ding, H., Wang, Z., Zhu, L., Liu, J., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq5331 · Cited by 27

Estrogen‐related receptor β activation and isoform shifting by cdc2‐like kinase inhibition restricts migration and intracranial tumor growth in glioblastoma

Tiek, D. M., Khatib, S. A., Trepicchio, C. J., Heckler, M. M., Divekar, S. D., Sarkaria, J. N., Glasgow, E. F., & Riggins, R. B. (2019) · The FASEB Journal · doi:10.1096/fj.201901075r · Cited by 24

Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma

Chen, K., Bridges, C. R., Lynton, Z., Lim, J. W. C., Stringer, B. W., Rajagopal, R., Wong, K., Ganesan, D., Ariffin, H., Day, B. W., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03352-3 · Cited by 23

Cold Plasma Discharge Tube Enhances Antitumoral Efficacy of Temozolomide

Yao, X., Yan, D., Lin, L., Sherman, J. H., Peters, K. B., Keir, S. T., & Keidar, M. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00018 · Cited by 22

Phosphorylation of NMDA 2B at S1303 in human glioma peritumoral tissue: implications for glioma epileptogenesis

Gao, X., Wang, H., Cai, S., Saadatzadeh, M. R., Hanenberg, H., Pollok, K. E., Cohen‐Gadol, A., & Chen, J. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14485 · Cited by 22

Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer

Connolly, N. P., Stokum, J. A., Schneider, C. S., Ozawa, T., Xu, S., Galisteo, R., Castellani, R. J., Kim, A. J., Simard, J. M., Winkles, J. A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174557 · Cited by 22

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

Khan, M. B., Ruggieri, R., Jamil, E., Tran, N. L., Gonzalez, C., Amaro-Mugridge, N. B., Gao, S. Y., MacDiarmid, J. A., Brahmbhatt, H. N., Sarkaria, J. N., et al. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00293-4 · Cited by 24

Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases

Vaidhyanathan, S., Wilken-Resman, B., Ma, D. J., Parrish, K. E., Mittapalli, R. K., Carlson, B. L., Sarkaria, J. N., & Elmquist, W. F. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229393 · Cited by 21

Challenges in the Delivery of Therapies to Melanoma Brain Metastases

Gampa, G., Vaidhyanathan, S., Wilken-Resman, B., Parrish, K. E., Markovic, S. N., Sarkaria, J. N., & Elmquist, W. F. (2016) · Current Pharmacology Reports · doi:10.1007/s40495-016-0072-z · Cited by 22

Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases

Gampa, G., Kim, M., Mohammad, A. S., Parrish, K. E., Mladek, A. C., Sarkaria, J. N., & Elmquist, W. F. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.253708 · Cited by 20

Convection-Enhanced Delivery of Auristatin-Conjugated Layer-by-Layer Nanoparticles for Glioblastoma Treatment

Pickering, A. J., Lamson, N. G., Marand, M. H., Straehla, J. P., & Hammond, P. T. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c16898 · Cited by 20

Mouse Models of Experimental Glioblastoma

Jin, F., Jin‐Lee, H. J., & Johnson, A. J. (2021) · Exon Publications eBooks · doi:10.36255/exonpublications.gliomas.2021.chapter2 · Cited by 18

Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment

Evgin, L., Huff, A. L., Kottke, T. J., Thompson, J., Molan, A. M., Driscoll, C. B., Schuelke, M. R., Shim, K. G., Wongthida, P., Ilett, E. J., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0013 · Cited by 20

Inhibition of TRPM7 with carvacrol suppresses glioblastoma functions in vivo

Alanazi, R., Nakatogawa, H., Wang, H., Ji, D., Luo, Z., Golbourn, B. J., Feng, Z., Rutka, J. T., & Sun, H. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15647 · Cited by 19

CHD2 Regulates Neuron–Glioma Interactions in Pediatric Glioma

Zhang, X., Duan, S., Apostolou, P. E., Wu, X., Watanabe, J., Gallitto, M., Barron, T., Taylor, K. R., Woo, P. J., Hua, X., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0012 · Cited by 24

Metal Oxide Laser Ionization Mass Spectrometry Imaging (MOLI MSI) Using Cerium(IV) Oxide

Basu, S. S., McMinn, M. H., Lopéz, B. G.-C., Regan, M. S., Randall, E. C., Clark, A. R., Cox, C. R., & Agar, N. Y. R. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b00894 · Cited by 19

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems

Shang, E., Zhang, Y., Shu, C., Ishida, C. T., Bianchetti, E., Westhoff, M., Karpel‐Massler, G., & Siegelin, M. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-33784-2 · Cited by 19

Chemically Modified Variants of Fenofibrate with Antiglioblastoma Potential

Stalińska, J., Zimoląg, E., Pianovich, N., Zapata, A., Lassak, A., Rak, M., Dean, M. J., Uçar, D. A., Wyczechowska, D. D., Culicchia, F., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.04.006 · Cited by 20

Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules

Burgenske, D. M., Talele, S., Pokorny, J. L., Mladek, A. C., Bakken, K. K., Carlson, B. L., Schroeder, M. A., He, L., Hu, Z., Gampa, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab162 · Cited by 18

Phenocopying Glioblastoma: A Review

Oraiopoulou, M., Tzamali, E., Papamatheakis, J. D., & Sakkalis, V. (2021) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2021.3111744 · Cited by 17

Identification of an EGFRvIII-JNK2-HGF/c-Met–Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion

Saunders, V. C., Lafitte, M., Adrados, I., Quereda, V., Feurstein, D., Ling, Y., Fallahi, M., Rosenberg, L. H., & Duckett, D. R. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.097774 · Cited by 19

Targeting Acid Ceramidase Inhibits Glioblastoma Cell Migration through Decreased AKT Signaling

Hawkins, C. C., Jones, A. B., Gordon, E. R., Williford, S. E., Harsh, Y., Ziebro, J. K., Libby, C. J., Sajina, G. C., Crossman, D. K., Cooper, S. J., et al. (2022) · Cells · doi:10.3390/cells11121873 · Cited by 18

Functional expression of CD73 on human natural killer cells

Chambers, A. M., Wang, J., Dao, T. N., Lupo, K. B., Veenhuis, P., Ayers, M. G., Slivova, V., Cohen‐Gadol, A., & Matosevic, S. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03219-z · Cited by 17

Rodent Glioma Models: Intracranial Stereotactic Allografts and Xenografts

Assi, H. H., Candolfi, M., Lowenstein, P. R., & Castro, M. G. (2012) · Neuromethods · doi:10.1007/7657_2011_33 · Cited by 17

PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas

Koncar, R. F., Chu, Z., Romick‐Rosendale, L. E., Wells, S. I., Chan, T. A.-T., Qi, X., & Bahassi, E. M. (2017) · Oncotarget · doi:10.18632/oncotarget.15015 · Cited by 17

Rodent Models to Analyze the Glioma Microenvironment

Hetze, S., Sure, U., Schedlowski, M., Hadamitzky, M., & Barthel, L. (2021) · ASN NEURO · doi:10.1177/17590914211005074 · Cited by 18

MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells

Das, A., Henderson, F. C., Alshareef, M., Porto, G. B. F., Kanginakudru, I., Infinger, L. K., Vandergrift, W. A., Lindhorst, S., Varma, A. K., Patel, S. J., et al. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02456-x · Cited by 16

Synthetic and systems biology principles in the design of programmable oncolytic virus immunotherapies for glioblastoma

Monie, D. D., Bhandarkar, A. R., Parney, I. F., Correia, C., Sarkaria, J. N., Vile, R. G., & Li, H. (2021) · Neurosurgical FOCUS · doi:10.3171/2020.12.focus20855 · Cited by 16

The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics

Straehla, J. P., Reardon, D. A., Wen, P. Y., & Agar, N. Y. R. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-040433 · Cited by 17

Assessing Nordihydroguaiaretic Acid Therapeutic Effect for Glioblastoma Multiforme

Manciu, F. S., Guerrero, J., Bennet, K. E., Chang, S.-Y., Rahman, M., Lopez, L. V. M., Chantigian, S., Castellanos, M., & Manciu, M. (2022) · Sensors · doi:10.3390/s22072643 · Cited by 16

Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma

Fernandez, E. G., Mai, W. X., Song, K., Bayley, N. A., Kim, J., Zhu, H., Pioso, M. S., Young, P., Andrasz, C. L., Cadet, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54138-9 · Cited by 15

Combined inhibition of Ref‐1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co‐culture models

Caston, R. A., Shah, F., Starcher, C. L., Wireman, R., Babb, O., Grimard, M., McGeown, J., Armstrong, L., Tong, Y., Пили, Р., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16132 · Cited by 13

Anti-glioblastoma effects of phenolic variants of benzoylphenoxyacetamide (BPA) with high potential for blood brain barrier penetration

Stalińska, J., Vittori, C., Ingraham, C. H., IV, Carson, S. C., Plaisance‐Bonstaff, K., Lassak, A., Faia, C., Colley, S. B., Peruzzi, F., Krzysztof Reiss, F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-07247-8 · Cited by 14

Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts

Porath, K. A., Regan, M. S., Griffith, J. I. G., Jain, S., Stopka, S. A., Burgenske, D. M., Bakken, K. K., Carlson, B. L., Decker, P. A., Vaubel, R. A., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac130 · Cited by 14

EGFR and EGFRvIII coopt host defense pathways promoting progression in glioblastoma

An, Z., Fan, Q.-W., Wang, L., Yoda, H., Barata, M. J., Jimenez‐Morales, D., Phillips, J. J., Swaney, D. L., Stevenson, E. J., Lee, E. N., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae182 · Cited by 14

DNA-PK Inhibition Shows Differential Radiosensitization in Orthotopic GBM PDX Models Based on DDR Pathway Deficits

Dragojevic, S., Smith, E. J., Regan, M. S., Stopka, S. A., Baquer, G., Xue, Z., Zhang, W., Connors, M. A., Kloeber, J. A., Hu, Z., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0003 · Cited by 13

In Vivo Efficacy of Tesevatinib in EGFR -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

Kizilbash, S. H., Gupta, S. K., Parrish, K. E., Laramy, J. K., Kim, M., Gampa, G., Carlson, B. L., Bakken, K. K., Mladek, A. C., Schroeder, M. A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0640 · Cited by 13

Matrix Hyaluronic Acid and Hypoxia Influence a CD133 + Subset of Patient-Derived Glioblastoma Cells

Chen, J.-W. E., Leary, S. E. S., Barnhouse, V. R., Sarkaria, J. N., & Harley, B. A. C. (2021) · Tissue Engineering Part A · doi:10.1089/ten.tea.2021.0117 · Cited by 13

IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma

Rechberger, J. S., Porath, K. A., Zhang, L., Nesvick, C. L., Schrecengost, R. S., Sarkaria, J. N., & Daniels, D. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14050922 · Cited by 13

Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients

Gagg, H., Williams, S. T., Conroy, S., Myers, K. N., McGarrity-Cottrell, C. L., Jones, C. G., Helleday, T., Rantala, J., Rominiyi, O., Danson, S. J., et al. (2023) · F1000Research · doi:10.12688/f1000research.135809.1 · Cited by 12

Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR : implications for drug development

Brown, K. E., Chagoya, G., Kwatra, S. G., Yen, T., Keir, S. T., Cooter, M. L., Hoadley, K. A., Rasheed, A., Lipp, E., McLendon, R. E., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13032 · Cited by 12

Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status

Thompson, E. M., Landi, D. B., Ashley, D. M., Keir, S. T., & Bigner, D. D. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2975-5 · Cited by 12

Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

Ji, J., Dragojevic, S., Callaghan, C. M., Smith, E. J., Talele, S., Zhang, W., Connors, M. A., Mladek, A. C., Hu, Z., Bakken, K. K., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0552 · Cited by 11

In vivo selection of anti-glioblastoma DNA aptamers in an orthotopic patient-derived xenograft model

Doherty, C. L., Wilbanks, B. A., Jain, S., Pearson, K. S., Bakken, K., Burgenske, D. M., Lett, N. W., Sarkaria, J. N., & Maher, L. J., III (2025) · NAR Cancer · doi:10.1093/narcan/zcaf005 · Cited by 11

A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma

Lin, W., Feathers, R. W., Cooper, L. M., Lewis‐Tuffin, L. J., Chen, J., Sarkaria, J. N., & Anastasiadis, P. Z. (2023) · JCI Insight · doi:10.1172/jci.insight.157491 · Cited by 11

Preclinical Systemic Pharmacokinetics, Dose Proportionality, and Central Nervous System Distribution of the ATM Inhibitor WSD0628, a Novel Radiosensitizer for the Treatment of Brain Tumors

Rathi, S., Oh, J., Zhang, W., Mladek, A. C., Garcia, D. A., Xue, Z., Burgenske, D. M., Zhang, W., Le, J., Zhong, W., et al. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001971 · Cited by 11

Therapeutic Hypothesis Testing With Rodent Brain Tumor Models

Wainwright, D. A., Horbinski, C., Hashizume, R., & James, C. D. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0523-1 · Cited by 11

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Valadez, J. G., Sarangi, A., Lundberg, C. J., & Cooper, M. K. (2014) · Journal of Visualized Experiments · doi:10.3791/50865 · Cited by 10

Activation of death-associated protein kinase in human peritumoral tissue: A potential therapeutic target

Gao, X., Wang, H., Pollok, K. E., Chen, J., & Cohen‐Gadol, A. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.03.044 · Cited by 9

Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma

Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0217 · Cited by 8

RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma

Jermakowicz, A. M., Kurimchak, A., Johnson, K. J., Bourgain‐Guglielmetti, F., Kaeppeli, S., Affer, M., Pradhyumnan, H., Suter, R. K., Walters, W. M., Cepero, M. L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60031-8 · Cited by 10

Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma

Meneceur, S., Linge, A., Meinhardt, M., Hering, S., Löck, S., Bütof, R., Krex, D., Schackert, G., Temme, A., Baumann, M. A., et al. (2020) · Cancers · doi:10.3390/cancers12040871 · Cited by 8

Molecular and Structural Traits of Insulin Receptor Substrate 1/LC3 Nuclear Structures and Their Role in Autophagy Control and Tumor Cell Survival

Lassak, A., Dean, M., Wyczechowska, D. D., Wilk, A. M., Marrero, L., Trillo-Tinoco, J., Boulares, A. H., Sarkaria, J. N., Valle, L. D., Peruzzi, F., et al. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00608-17 · Cited by 8

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models

Keir, S. T., Chandramohan, V., Hemphill, C., Grandal, M. M., Melander, M. C., Pedersen, M. W., Horak, I. D., Kragh, M., Desjardins, A., Friedman, H. S., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2832-6 · Cited by 8

Single-cell based elucidation of molecularly-distinct glioblastoma states and drug sensitivityPreprint

Ding, H., Burgenske, D. M., Zhao, W., Subramaniam, P. S., Bakken, K. K., He, L., Alvarez, M. J., Laise, P., Paull, E., Spinazzi, E. F., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/675439 · Cited by 8

Coordinated Targeting of S6K1/2 and AXL Disrupts Pyrimidine Biosynthesis in PTEN-Deficient Glioblastoma

Behrmann, C. A., Ennis, K. N., Sarma, P., Wetzel, C., Clark, N. A., Handorf, K. M. V., Vallabhapurapu, S., Andreani, C., Reigle, J. K., Scaglioni, P. P., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0631 · Cited by 7

Modeling Glioblastoma for Translation: Strengths and Pitfalls of Preclinical Studies

D’Antonio, C., & Liguori, G. L. (2025) · Biology · doi:10.3390/biology14111490 · Cited by 8

Lipidomic Analysis of Glioblastoma Multiforme Using Mass Spectrometry

Ha, S., Showalter, G., Cai, S., Wang, H., Liu, W., Cohen‐Gadol, A., Sarkaria, J. N., Rickus, J. L., Springer, J., Adamec, J., et al. (2014) · Current Metabolomics · doi:10.2174/2213235x02666141107215357 · Cited by 7

Drug Repositioning Screen on a New Primary Cell Line Identifies Potent Therapeutics for Glioblastoma

Senbabaoglu, F., Aksu, A. C., Cingöz, A., Seker-Polat, F., Börklü, E., Solaroğlu, İ., & Onder, T. B. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.578316 · Cited by 6

Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models

Qiu, Y., Li, Z., Copland, J. A., Mehrling, T., & Tun, H. W. (2018) · Oncotarget · doi:10.18632/oncotarget.25588 · Cited by 7

Clinical and Research Applications of a Brain Tumor Tissue Bank in the Age of Precision Medicine

Snyder, J., Poisson, L., Noushmehr, H., Castro, A. V., deCarvalho, A. C., Robin, A. M., Mukherjee, A., Lee, I. Y., & Walbert, T. (2019) · Personalized Medicine · doi:10.2217/pme-2018-0102 · Cited by 7

Targeting the RhoGEF βPIX/COOL-1 in Glioblastoma: Proof of Concept Studies

Connor, K., Murray, D. W., Jarzabek, M. A., Tran, N. L., White, K., Dicker, P., Sweeney, K. J., O’Halloran, P. J., MacCarthy, B., Shiels, L. P., et al. (2020) · Cancers · doi:10.3390/cancers12123531 · Cited by 7

ABCC4 suppresses glioblastoma progression and recurrence by restraining cGMP-PKG signalling

Chiang, J., Wei, S., Chang, H.-J., Chen, D.-C., Wang, H.-L., Lei, F., Wei, K.-Y., Huang, Y., Wang, C.-C., & Hsieh, C. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02581-2 · Cited by 6

Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma

Kaanoglu, H., Adefolaju, A., Fraley, C., Shobande, M., Dasari, R., Mann, B., Bell, N., Keir, S. T., Higgins, D. M. O., Kram, D. E., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-1098 · Cited by 6

Methods for intratumoral microdialysis probe targeting and validation in murine brain tumor models

Rajani, K. R., Olson, I., Jacobs, J. J., Riviere-Cazaux, C., Burns, K., Carlstrom, L. P., Schroeder, M. A., Oh, J., Howe, C. L., Rahman, M., et al. (2021) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2021.109321 · Cited by 6

Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment

Das, A., Alshareef, M., Porto, G. B. F., Infinger, L. K., Vandergrift, W. A., Lindhorst, S., Varma, A. K., Patel, S. J., & Cachia, D. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.117102 · Cited by 6

Cell migration simulator-based biomarkers for glioblastoma

Hou, J., McMahon, M. M., Jubenville, T. A., Sarkaria, J. N., Chen, C. C., & Odde, D. J. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae184 · Cited by 5

WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models

Conage‐Pough, J. E., Stopka, S. A., Oh, J., Mladek, A. C., Burgenske, D. M., Regan, M. S., Baquer, G., Decker, P. A., Carlson, B. L., Bakken, K. K., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad066 · Cited by 5

Bone Marrow Mesenchymal Stem Cells Promote Ovarian Cancer Cell Proliferation via Cytokine Interactions

Wang, K., Chang, Y., & Ding, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126746 · Cited by 4

A Repurposed Drug Selection Pipeline to Identify CNS-Penetrant Drug Candidates for Glioblastoma

Ntafoulis, I., Koolen, S. L. W., van Tellingen, O., den Hollander, C. W. J., Sabel-Goedknegt, H., Dijkhuizen, S., Haeck, J. C., Reuvers, T. G. A., de Bruijn, P., van den Bosch, T. P. P., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17121687 · Cited by 4

Optimization, Characterization, and Comparison of Two Luciferase-Expressing Mouse Glioblastoma Models

Rodgers, L. T., Schulz, J., Maloney, B. J., Hartz, A. M. S., & Bauer, B. (2024) · Cancers · doi:10.3390/cancers16111997 · Cited by 4

The impact of therapeutic radiation on drug distribution across the blood-brain barrier in normal mouse brain and orthotopic glioblastoma tumors

Zhang, W., Grams, M. P., Oberoi, R. K., Oh, J., Decker, P. A., Sio, T. T.-W., Talele, S., Wilson, Z. C., Connors, M. A., Bakken, K. K., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf093 · Cited by 4

EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma

Nayab, A., Mughal, N., Angez, M., Xing, S., Burma, A. M., Balla, H., Kizilbash, S. H., Yang, X., Maqbool, M. A., Arain, F. M., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx8398 · Cited by 3

XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma

Mapunda, J. A., Suzuki, Y., Burgenske, D. M., Decker, P. A., Zhang, L., Eckel‐Passow, J. E., Sarkaria, J. N., & Kitange, G. J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1633580 · Cited by 3

Development of Novel Neratinib and Docetaxel Core-Loaded and Trastuzumab Surface-Conjugated Nanoparticle for Treatment of HER-2 Positive Breast Cancer

Ejigah, V., Battogtokh, G., Mandala, B., & Akala, E. O. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17101265 · Cited by 3

Linear and nonlinear rheology of liberase-treated breast cancer tumors

Corder, R. D., Vachieri, R. B., Martin, M. E., Taylor, D. K., Fleming, J. M., & Khan, S. A. (2023) · Biomaterials Science · doi:10.1039/d3bm00038a · Cited by 3

Computational modeling and synthesis of pyridine variants of benzoyl-phenoxy-acetamide with high glioblastoma cytotoxicity and brain tumor penetration

Ingraham, C. H., Stalińska, J., Carson, S. C., Colley, S. B., Rak, M., Lassak, A., Peruzzi, F., Reiss, K., & Jursic, B. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-39236-w · Cited by 4

The impact of initial tumor microenvironment on imaging phenotype

Nagaraja, T. N., deCarvalho, A. C., Brown, S. L., Griffith, B. D., Farmer, K. G., Irtenkauf, S. M., Hasselbach, L. A., Mukherjee, A., Bartlett, S., Valadie, O. G., et al. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100315 · Cited by 3

Impact of the radiated brain microenvironment on a panel of human patient-derived xenograftsPreprint

Zhang, J., Olson, I., Carlstrom, L. P., Rahman, M., Rajani, K. R., Gupta, K., Liu, L., Tang, Z., Sananikone, E. F., Dong, A. (., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.03.132365 · Cited by 3

Tumor-responsive, multifunctional CAR-NK cells cooperate with impaired autophagy to infiltrate and target glioblastomaPreprint

Wang, J., Torregrosa‐Allen, S. E., Elzey, B. D., Utturkar, S. M., Lanman, N. A., Bernal-Crespo, V., Behymer, M. M., Knipp, G. T., Yun, Y., Veronesi, M. C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.07.330043 · Cited by 3

Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma

Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0244 · Cited by 2

Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors

Rathi, S., Mladek, A. C., Oh, J., Dragojevic, S., Burgenske, D. M., Zhang, W., Talele, S., Zhang, W., Bakken, K. K., Carlson, B. L., et al. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.002002 · Cited by 2

Radiotherapy plus neoadjuvant and concomitant IL-13Rα2-directed immunotoxin therapy for diffuse intrinsic pontine glioma

Rechberger, J. S., Vanbilloen, W. J. F., Nonnenbroich, L. F., Ge, J., Schrecengost, R. S., Vaubel, R. A., Zhang, L., & Daniels, D. J. (2026) · Communications Biology · doi:10.1038/s42003-025-09155-9 · Cited by 2

Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients

Gagg, H., Williams, S. T., Conroy, S., Myers, K. N., McGarrity-Cottrell, C. L., Jones, C. G., Helleday, T., Rantala, J., Rominiyi, O., Danson, S. J., et al. (2024) · F1000Research · doi:10.12688/f1000research.135809.2 · Cited by 2

Fluorescence-Guided Resection of GL261 Red-FLuc and TRP-mCherry-FLuc Mouse Glioblastoma Tumors

Rodgers, L. T., Maloney, B. J., Hartz, A. M. S., & Bauer, B. (2025) · Cancers · doi:10.3390/cancers17050734 · Cited by 2

Bypassing Blood‐Brain Barrier and Glucose Dependency of Anti‐Glioblastoma Drug Candidates Targeting Mitochondrial Respiration

Ingraham, C. H., Polanía-Villanueva, D., Macaluso, A., Tramuta, A., Vittori, C., Hunter, J., Rak, M., Claudio, P. P., Ibrahim, M. A., Valle, L. D., et al. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70062 · Cited by 2

A micellar nanoprobe for fluorescence image-guided delineation of glioblastoma margins

Ali, M., van der Kuil, K. T. H., Khodakivskyi, P. V., de Bruijn, P., Koolen, S. L. W., Lamfers, M. L. M., Gao, Z., Amin, M., Goun, E. A., Dirven, C. M. F., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107881 · Cited by 2

A reproducible brain tumour model established from human glioblastoma biopsies

Wang, J., Miletić, H., Sakariassen, P. Ø., Huszthy, P. C., Jacobsen, H. K., Brekkå, N., Li, X., Zhao, P., Mørk, S. J., Chekenya, M., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-465 · Cited by 105

Establishment of Stereotactic Orthotopic Brain Tumor Xenografts in Mice: Technical Report

Gholamin, S., Feroze, A. H., Mitra, S. S., Kahn, S. A., & Cheshier, S. H. (2013) · Cureus · doi:10.7759/cureus.150 · Cited by 9

The development of xenograft glioblastoma implants in nude mice brain.

Brehar, F. M., Ciurea, A. V., Chivu‐Economescu, M., Zărnescu, O., Rădulescu, R., & Dragu, D. (2008) · PubMed Central · Cited by 12

Establishing Orthotopic Xenograft Glioblastoma Models for Use in Preclinical Development

Basso, J., Sereno, J., Fortuna, A. C., Castelo-Branco, M. S., & Vitorino, C. (2020) · Neuromethods · doi:10.1007/978-1-0716-1052-7_12 · Cited by 5

Orthotopic Patient-Derived Glioblastoma Xenografts in Mice

Xu, Z., Kader, M. E., Sen, R., & Placantonakis, D. G. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7659-1_14 · Cited by 24